P&G guidance
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble has upgraded its sales and EPS guidance for the second quarter of fiscal year 2006 due to strong sales and lower-than-expected costs for the Gillette acquisition, the firm states in a release Dec. 13. The company projects 25%-26% sales growth for the quarter, in the upper range of its previous estimates. EPS guidance has also moved to the upper margin of previous estimates to $0.68-$0.69, the Cincinnati-based firm reports. P&G estimates that its recently acquired Gillette business will dilute second-quarter earnings by $.08-$.10 per share rather than the previously forecasted $.09-.$12 per share. Additionally, Gillette turned out a strong performance in the second quarter with sales increasing 17% versus the previously estimated "flat to low-single digit sales growth," P&G states. The firm's $57 bil. purchase of Gillette closed in October...
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.